W
Watsky Eric Jacob
Researcher at Pfizer
Publications - 28
Citations - 4229
Watsky Eric Jacob is an academic researcher from Pfizer. The author has contributed to research in topics: Partial agonist & Placebo. The author has an hindex of 15, co-authored 28 publications receiving 4070 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
Douglas E. Jorenby,J. Taylor Hays,Nancy A. Rigotti,Salomon Azoulay,Watsky Eric Jacob,Kathryn E. Williams,Clare B. Billing,Jason Gong,Karen R. Reeves +8 more
TL;DR: Varenicline is an efficacious, safe, and well-tolerated smoking cessation pharmacotherapy and its short-term and long-term efficacy exceeded that of both placebo and bupropion SR.
Journal ArticleDOI
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
David Gonzales,Stephen I. Rennard,Mitchell A. Nides,Cheryl Oncken,Salomon Azoulay,Clare B. Billing,Watsky Eric Jacob,Jason Gong,Kathryn E. Williams,Karen R. Reeves +9 more
TL;DR: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficient than sustained-release bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks.
Journal ArticleDOI
Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
Mitchell A. Nides,Cheryl Oncken,David Gonzales,Stephen I. Rennard,Watsky Eric Jacob,Rich Anziano,Karen R. Reeves +6 more
TL;DR: Varenicline tartrate demonstrated both short-term effectiveness (1 mg twice daily and 1 mg once daily) and long-term efficacy (1mg twice daily) vs placebo and may provide a novel therapy to aid smoking cessation.
Journal ArticleDOI
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Cheryl Oncken,David Gonzales,Mitchell A. Nides,Stephen I. Rennard,Watsky Eric Jacob,Clare B. Billing,R.J. Anziano,Karen R. Reeves +7 more
TL;DR: Varenicline tartrate, 0.5 mg and 1.0 mg twice daily, is efficacious for smoking cessation.
Journal ArticleDOI
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
Edmund P. Harrigan,J.J. Miceli,R.J. Anziano,Watsky Eric Jacob,Karen R. Reeves,Neal R. Cutler,T. John Sramek,Thomas Shiovitz,Michelle Middle +8 more
TL;DR: The theoretical risk of cardiotoxicity associated with QTc prolongation should be balanced against the substantial clinical benefits associated with atypical antipsychotics and the likelihood of other toxicities.